Karl W., German histologist, 1860-1945. See: Hürthle cell, Hürthle cell adenoma, Hürthle cell carcinoma.
References in periodicals archive ?
Interestingly, Hurthle cell carcinomas, irrespective of the degree of differentiation, tended to have the longest survivals.
Through April 2004, 23 patients have been enrolled: 8 with colorectal cancer; 3 with renal cell carcinoma; 2 each with sarcoma, melanoma, or breast cancer; 1 each with non-small cell lung cancer, Hurthle cell sarcoma of thyroid, salivary gland carcinoma, basal cell carcinoma, pseudomyxoma, or carcinoma of unknown origin.
99m]Tc-Sestamibi scintiscan, which has been reported to identify Hurthle cell tumors and their metastases,[22] as well as the raised thyroglobulin levels, supported the likelihood that bone metastases could be attributed to the thyroid oncocytic carcinoma.
1-4] The true oncocytic tumors are classified as Hurthle cell tumors, which are characterized by distinct cytology and clinical behavior.
The total number of cases with FNA diagnosis of neoplastic (13 cases) and nonneoplastic (17 cases) Hurthle cell lesions remained unaltered after the application of new criteria.
A fine needle aspiration of the right thyroid revealed a colloid nodule with rare Hurthle cells.
Five partial responses (>30% tumor regression by RECIST) were observed, including three in papillary renal cell cancer, one in medullary thyroid cancer, and one in hurthle cell thyroid cancer.
The "suspicious" category included follicular neoplasm, Hurthle cell tumor, and aspirates with atypical features suggestive of, but not diagnostic for, malignancy.
As reported by the investigators, four patients have had partial responses (papillary renal cell carcinoma [3] and Hurthle cell carcinoma [1]); four patients have had minimal responses (carcinoid [1], colorectal [1], melanoma [1] and medullary thyroid [1]); and seven patients have had stable disease for 3 to 7 months (colorectal [3], renal cell [1], billiary [1], urethral [1] and thyroid [1]).
1,2,5,6] We report a case that showed coexistent tall cell variant of papillary carcinoma and Hurthle cell carcinoma.
Lenvatinib is indicated for the treatment of adult patients with locally advanced or metastatic, progressive differentiated (papillary, follicular, Hurthle cell) thyroid carcinoma (DTC) refractory to radioactive iodine (RAI).
This applies to glands with many different pathologies, including papillary thyroid carcinoma, Hashimoto thyroiditis, Hurthle cell adenoma, and multinodular goiter.